Skip Nav Destination
Issues
1 July 2009
-
Cover Image
Cover Image
X-ray co-crystal structure of the small molecule inhibitor GDC-0941 bound to human PI3 kinase gamma isoform (PDB code 3dbs). The image shows the drug bound in the ATP binding pocket of the kinase. GDC-0941, now in Phase I clinical trial, was evolved from the earlier inhibitors PI-103, PI-540, and PI-620, as described by Raynaud, Workman and colleagues in this issue. The authors thank Drs Rob Van Montfort and Isaac Westwood, Sections of Cancer Therapeutics and Structural Biology, The Institute of Cancer Research (ICR), for the expert preparation of the image, which was made with the program CCP4MG. For details, see the article by Raynaud and colleagues on page 1725. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Issue Sections
Research Articles
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Florence I. Raynaud; Suzanne A. Eccles; Sonal Patel; Sonia Alix; Gary Box; Irina Chuckowree; Adrian Folkes; Sharon Gowan; Alexis De Haven Brandon; Francesca Di Stefano; Angela Hayes; Alan T. Henley; Letitia Lensun; Giles Pergl-Wilson; Anthony Robson; Nahid Saghir; Alexander Zhyvoloup; Edward McDonald; Peter Sheldrake; Stephen Shuttleworth; Melanie Valenti; Nan Chi Wan; Paul A. Clarke; Paul Workman
Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells
Florence Lefranc; Sébastien Sauvage; Gwendoline Van Goietsenoven; Véronique Mégalizzi; Delphine Lamoral-Theys; Olivier Debeir; Sabine Spiegl-Kreinecker; Walter Berger; Véronique Mathieu; Christine Decaestecker; Robert Kiss
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
Christina L. Roland; Sean P. Dineen; Kristi D. Lynn; Laura A. Sullivan; Michael T. Dellinger; Leila Sadegh; James P. Sullivan; David S. Shames; Rolf A. Brekken
GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models
Mary Ann Hardwicke; Catherine A. Oleykowski; Ramona Plant; Jamin Wang; Qiaoyin Liao; Katherine Moss; Ken Newlander; Jerry L. Adams; Dashyant Dhanak; Jingsong Yang; Zhihong Lai; David Sutton; Denis Patrick
Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
Kenneth Thress; Terry MacIntyre; Haiyun Wang; Dave Whitston; Zhong-Ying Liu; Ethan Hoffmann; Tao Wang; Jeffrey L. Brown; Kevin Webster; Charles Omer; Peter E. Zage; Lizhi Zeng; Patrick A. Zweidler-McKay
Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity
Huw D. Thomas; Kappusamy Saravanan; Lan-Zhen Wang; Mei-Ju Lin; Julian S. Northen; Hannah Barlow; Marion Barton; David R. Newell; Roger J. Griffin; Bernard T. Golding; Nicola J. Curtin
Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout
Matthias Versele; Willem Talloen; Cindy Rockx; Tamara Geerts; Boud Janssen; Tom Lavrijssen; Peter King; Hinrich W.H. Göhlmann; Martin Page; Tim Perera
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
Kate F. Byth; Andrew Thomas; Gareth Hughes; Cheryl Forder; Alexandra McGregor; Catherine Geh; Sandra Oakes; Clive Green; Mike Walker; Nicholas Newcombe; Stephen Green; Jim Growcott; Andy Barker; Robert W. Wilkinson
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
Annamaria Rapisarda; Melinda Hollingshead; Badarch Uranchimeg; Carrie A. Bonomi; Suzanne D. Borgel; John P. Carter; Bradley Gehrs; Mark Raffeld; Robert J. Kinders; Ralph Parchment; Miriam R. Anver; Robert H. Shoemaker; Giovanni Melillo
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity
Thomas D. Pfister; William C. Reinhold; Keli Agama; Shalu Gupta; Sonny A. Khin; Robert J. Kinders; Ralph E. Parchment; Joseph E. Tomaszewski; James H. Doroshow; Yves Pommier
Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors
Sébastien Grosso; Alexandre Puissant; Maeva Dufies; Pascal Colosetti; Arnaud Jacquel; Kevin Lebrigand; Pascal Barbry; Marcel Deckert; Jill Patrice Cassuto; Bernard Mari; Patrick Auberger
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib
Judith Loeffler-Ragg; Doris Mueller; Gabriele Gamerith; Thomas Auer; Sergej Skvortsov; Bettina Sarg; Ira Skvortsova; Klaus J. Schmitz; Hans-Jörg Martin; Jens Krugmann; Hakan Alakus; Edmund Maser; Jürgen Menzel; Wolfgang Hilbe; Herbert Lindner; Kurt W. Schmid; Heinz Zwierzina
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database
Josiah N. Orina; Anna Maria Calcagno; Chung-Pu Wu; Sudhir Varma; Joanna Shih; Min Lin; Gabriel Eichler; John N. Weinstein; Yves Pommier; Suresh V. Ambudkar; Michael M. Gottesman; Jean-Pierre Gillet
Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma
Dana-Lynn T. Koomoa; Tamas Borsics; David J. Feith; Craig C. Coleman; Christopher J. Wallick; Ivonne Gamper; Anthony E. Pegg; André S. Bachmann
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.